AB SCIENCE SA (AB.PA) Stock Price & Overview

EPA:AB • FR0010557264

Current stock price

1.224 EUR
+0 (+0.33%)
Last:

The current stock price of AB.PA is 1.224 EUR. Today AB.PA is up by 0.33%. In the past month the price decreased by -3.37%. In the past year, price decreased by -11.29%.

AB.PA Key Statistics

52-Week Range0.97 - 1.73
Current AB.PA stock price positioned within its 52-week range.
1-Month Range1.219 - 1.398
Current AB.PA stock price positioned within its 1-month range.
Market Cap
81.004M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.15
Dividend Yield
N/A

AB.PA Stock Performance

Today
+0.33%
1 Week
-1.67%
1 Month
-3.37%
3 Months
-3.07%
Longer-term
6 Months -3.52%
1 Year -11.30%
2 Years -51.26%
3 Years -78.33%
5 Years -91.75%
10 Years -88.76%

AB.PA Stock Chart

AB SCIENCE SA / AB Daily stock chart

AB.PA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to AB.PA. When comparing the yearly performance of all stocks, AB.PA is a bad performer in the overall market: 81.74% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AB.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AB.PA. AB.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AB.PA Earnings

Next Earnings DateMay 11, 2026
Last Earnings DateSep 30, 2025
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

AB.PA Forecast & Estimates

9 analysts have analysed AB.PA and the average price target is 3.79 EUR. This implies a price increase of 210% is expected in the next year compared to the current price of 1.224.

For the next year, analysts expect an EPS growth of 65.85% and a revenue growth -3% for AB.PA


Analysts
Analysts84.44
Price Target3.79 (209.64%)
EPS Next Y65.85%
Revenue Next Year-3%

AB.PA Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

AB.PA Financial Highlights

Over the last trailing twelve months AB.PA reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS decreased by -23.25% compared to the year before.


Income Statements
Revenue(TTM)1.03M
Net Income(TTM)-8.54M
Industry RankSector Rank
PM (TTM) N/A
ROA -40.25%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%1.33%
Sales Q2Q%-8.04%
EPS 1Y (TTM)-23.25%
Revenue 1Y (TTM)-5.08%

AB.PA Ownership

Ownership
Inst Owners0%
Shares66.18M
Float45.80M
Ins Owners30.8%
Short Float %N/A
Short RatioN/A

AB.PA Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
SNW SANOFI9.01184.552B
1SAN SANOFI9.01184.552B
SAN SANOFI9.02184.503B
UCB UCB SA24.7848.55B
UNC UCB SA24.2748.55B
1MRK MERCK KGAA13.4148.217B
MRK MERCK KGAA13.0946.869B
1BAYN BAYER AG-REG8.3638.422B
BAYN BAYER AG-REG8.5737.956B
IPN IPSEN12.5912.764B
REC RECORDATI INDUSTRIA CHIMICA15.699.511B
TUB FINANCIERE DE TUBIZE N/A9.436B
VIRP VIRBAC SA15.262.777B

About AB.PA

Company Profile

AB logo image AB Science SA operates as a pharmaceutical company, which engages in the research, development, and marketing of synthetic therapeutic molecules for pathologies with high medical need, in diseases of the central nervous system, cancers, and inflammatory diseases. The company is headquartered in Paris, Ile-De-France and currently employs 37 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

Company Info

IPO: 2010-04-21

AB SCIENCE SA

3, avenue George V

Paris ILE-DE-FRANCE FR

Employees: 40

AB Company Website

AB Investor Relations

Phone: 33147200014

AB SCIENCE SA / AB.PA FAQ

What does AB do?

AB Science SA operates as a pharmaceutical company, which engages in the research, development, and marketing of synthetic therapeutic molecules for pathologies with high medical need, in diseases of the central nervous system, cancers, and inflammatory diseases. The company is headquartered in Paris, Ile-De-France and currently employs 37 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.


What is the current price of AB stock?

The current stock price of AB.PA is 1.224 EUR. The price increased by 0.33% in the last trading session.


Does AB stock pay dividends?

AB.PA does not pay a dividend.


What is the ChartMill rating of AB SCIENCE SA stock?

AB.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the analyst forecast for AB.PA stock?

9 analysts have analysed AB.PA and the average price target is 3.79 EUR. This implies a price increase of 210% is expected in the next year compared to the current price of 1.224.


What is AB SCIENCE SA worth?

AB SCIENCE SA (AB.PA) has a market capitalization of 81.00M EUR. This makes AB.PA a Micro Cap stock.